Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatitis B: early-phase trial registry
11 of 34 indexed Hepatitis B trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #451 of 28,707 conditions by registered trial count.
34 US clinical trials · 11 currently recruiting · #451 of 28,707 conditions by registered trial count
Hepatitis B: 34 US clinical trials tracked, 11 recruiting.
Hepatitis B is the subject of 34 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.
Enrollment posture brief
Registry condition hepatitis-b
OPEN 11 | RECR 32% | LATE 8 | EARLY 13 | RANK #451 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Carcinoma, Non-Small Cell Lung (32% recruiting · 133 trials)
Hepatitis B lists 11 open slots (32% of 34 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatitis B on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatitis B is recruiting below its size-band peers.
11 of 34 indexed trials (32.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatitis B trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 34 trials (11.8%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatitis B enrolment sits around 200 participants.
Median target enrolment is 200 among the 33 trials that report a genuine target (sentinel values excluded). 14 of those (42.4%) plan for fewer than 100 participants.
-
Hepatitis B splits between interventional and observational designs.
23 interventional and 11 observational studies make up this index (67.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
34 total, page 1 of 1
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
Syneos Health
NCT00404989
Evaluation of Patients With Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001971
National Liver Cancer Screening Trial
University of Texas Southwestern Medical Center
NCT06084234
Blood Collection Biorepository for Liver Disease Research
State University of New York at Buffalo
NCT03025074
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
GlaxoSmithKline
NCT04954859
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Mercy Medical Center
NCT04588077
Liver Cancer Disparities in American Indian and Alaska Native Persons
University of Washington
NCT05304234
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
Rockefeller University
NCT05856890
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
GlaxoSmithKline
NCT07168356
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
Rockefeller University
NCT05272735
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
University of Maryland, Baltimore
NCT04843852
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
NCT05064553
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
GlaxoSmithKline
NCT06537414
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B
University of Pennsylvania
NCT01298037
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
GlaxoSmithKline
NCT06497504
HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B
University of Pennsylvania
NCT01796457
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05551273
Entecavir to TAF Switch
Thomas Jefferson University
NCT03489239
Healthy Planet Hepatitis B
University of California, Davis
NCT04503993
Thousand Asian American Study
University of California, Davis
NCT02596438
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04193189
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
National Institutes of Health Clinical Center (CC)
NCT01350648
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
University of North Carolina, Chapel Hill
NCT00142740
Prevention of Recurrent Hepatitis B After Liver Transplantation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00059267
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013871
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
Bristol-Myers Squibb
NCT00065507
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
Bristol-Myers Squibb
NCT00096785
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Gilead Sciences
NCT01590641
Simvastatin for the Treatment of Chronic Hepatitis B
Bader, Ted, M.D.
NCT00994773
Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT
University of Washington
NCT00230477
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Baylor College of Medicine
NCT01988753
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients
Baylor Research Institute
NCT04199715
Pentavalent DTaP-Hep B-IPV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00133445
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
Bristol-Myers Squibb
NCT00051038
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 7 |
| Phase 3 | 4 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatitis B records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatitis B trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatitis B page
34 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Hepatitis B trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Hepatitis B trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis B condition card totals 34 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.